Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

These three dividend payers have an average yield of 4.5%. David Harrell: Hi, I’m David Harrell, editor of the Morningstar ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell.

Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a ...

Central Indiana’s radiopharmaceutical industry continues to expand rapidly, earning the state a new title from the U.S.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.